Results 41 to 50 of about 73,416 (250)

Targeting the MDM2‐MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer

Molecular Oncology, EarlyView.
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini, Giada Mele, Marika Attili, Maria Rita Assenza, Fulvio Saccoccia, Francesca Sardina, Cinzia Rinaldo, Roberto Massari, Nicola Tirelli, Alfredo Pontecorvi, Fabiola Moretti   +10 more
wiley   +1 more source

Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGFβ signalling and EMT [PDF]

, 2011
Ubiquitin-dependent mechanisms have emerged as essential regulatory elements controlling cellular levels of Smads and TGFß-dependent biological outputs such as epithelial–mesenchymal transition (EMT). In this study, we identify a HECT E3 ubiquitin ligase
A Chantry, A Hata, CH Heldin, CS Lutz, D Javelaud, F Bernassola, F Murray-Zmijewski, FJ McDonald, G Pirozzi, H Li, H Xu, H Zhu, HM Xu, J Tazi, J Xu, J Zavadil, L Levy, M Flasza, NJ Foot, NS Raikwar, P Kavsak, P Lönn, PJ Lu, S Bonni, S Danckwardt, S Hong, S M Soond, S Wicks, S Wiesner, S Zhang, T Atsumi, T Mund, TW Nilsen, U Valcourt, V Ellenrieder, W Li   +35 more
core   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

Discovery of cellular regulation by protein degradation [PDF]

, 2008
What follows is a story of some of the lab’s adventures mentioned above, including the inventions of new biochemical and genetic methods. This account stems, in part, from previous descriptions of the early history of the Ub field (31,32).
Alagramam, Alexander Varshavsky, Alfageme, An, Aulner, Bachmair, Bachmair, Bakayev, Baker, Baker, Balzi, Barsoum, Bartel, Bartel, Blattes, Byrd, Chau, Ciechanover, Ciechanover, Ciechanover, Clarke, Coelho, D'Ambrosio, Damelin, Davydov, Demartino, Deming, Dinardo, Ditzel, Dohmen, Dohmen, Dohmen, Du, Dunnwald, Evans, Ferber, Finley, Finley, Finley, Fried, Garner, Geiss-Friedlander, Gisler, Glotzer, Goebl, Goldknopf, Gonda, Goto, Graciet, Grigoryev, Haering, Haggarty, Hanna, Harper, Hauf, Hershko, Hershko, Hershko, Hershko, Hershko, Hicke, Hochstrasser, Hochstrasser, Holm, Hou, Hu, Hu, Hu, Huang, Hunter, Inobe, Jentsch, Johnson, Johnson, Johnson, Johnsson, Johnsson, Kaiji, Kerppola, Kerscher, Kornberg, Kwon, Kwon, Kwon, Kwon, Kwon, Lee, Levinger, Levinger, Levinger, Levinger, Li, Lou, Lévy, Marunouchi, Matsumoto, McGrath, Meyer-Almes, Milutinovich, Minsky, Mogk, Mukhopadhyay, Nasmyth, Peters, Pickart, Rao, Roninson, Rubinsztein, Rumpf, Sasaki, Shamu, Sheng, Shintomi, Shrader, Skoufias, Soffer, Solomon, Steck, Strauss, Sundin, Sundin, Suzuki, Tarassov, Tasaki, Tasaki, Tobias, Tobias, Turner, Turner, Uemura, Uhlmann, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Varshavsky, Wang, Wilkinson, Winter, Wittke, Woelk, Xia, Xie, Xie, Yi, Zenker, Özkaynak, Özkaynak   +158 more
core   +3 more sources

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

BRCA1 is a histone-H2A-specific ubiquitin ligase [PDF]

, 2014
The RING domain proteins BRCA1 and BARD1 comprise a heterodimeric ubiquitin (E3) ligase that is required for the accumulation of ubiquitin conjugates at sites of DNA damage and for silencing at DNA satellite repeat regions. Despite its links to chromatin,
Bentley, Brzovic, Brzovic, Buchwald, Campbell, Chen, Christensen, Coleman, Doil, Elderkin, Gospodinov, Hashizume, Leung, Li, Mallery, Mattiroli, Mattiroli, Morris, Moynahan, Paull, Reid, Ruffner, Shakya, Stewart, Thomas, Venkitaraman, Wang, Wu, Xu, Zhu   +29 more
core   +7 more sources

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Identification of novel components of Trypanosoma brucei editosomes [PDF]

, 2003
The editosome is a multiprotein complex that catalyzes the insertion and deletion of uridylates that occurs during RNA editing in trypanosomatids. We report the identification of nine novel editosome proteins in Trypanosoma brucei.
Carmean, Nicole, Ernst, Nancy L, Panigrahi, Aswini K, Salavati, Reza, Schnaufer, Achim, Stuart, Kenneth, Wang, Bingbing   +6 more
core   +2 more sources

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

Molecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova, Dominika Maurencova, Barbora Salovska, Marek Kratky, Tomas Mracek, Zuzana Korandova, Alena Pecinova, Pavla Vasicova, David Rysanek, Ladislav Andera, Ivo Fabrik, Rudolf Kupcik, Pavel Kashmel, Pinky Sultana, Vojtech Tambor, Jiri Bartek, Josef Novak, Marie Vajrychova, Zdenek Hodny   +18 more
wiley   +1 more source